Our mission is to provide rheumatologists with deeper clinical insights and help enable more effective management of patients with autoimmune and inflammatory diseases. Our goal is to create a broad portfolio of specialty diagnostic tests that will enable more effective patient management and improve patient outcomes.
The Company is developing novel tests that complement Vectra DA to help rheumatologists manage other autoimmune and inflammatory diseases.
Crescendo Bioscience is advancing its pipeline by leveraging its multi-biomarker platform to develop new tests. We are focused on assay development that aids in the diagnosis of multiple inflammatory diseases, including psoriatic arthritis (PsA). PsA is a chronic, heterogeneous, debilitating autoimmune disease that affects nearly 38 million people worldwide. Early, accurate diagnosis of PsA is crucial to optimally managing the disease and minimizing joint damage and long-term disability.
PsA has a complex biology with multiple pathways that are expressed differently in each patient. Working with collaborators from leading academic institutions, Crescendo Bioscience is building a comprehensive understanding of the underlying biology of PsA in order to provide an accurate molecular analysis of the disease that will aid in the diagnosis of individual patients. A multi-biomarker assay that provides an objective and quantitative approach to diagnosing PsA, which captures the complex pathophysiology of PsA, will impact a wide range of patients.